aTyr Pharma (NASDAQ:ATYR) Shares Down 2.3% – What’s Next?

aTyr Pharma, Inc. (NASDAQ:ATYR) shares were down 2.3% during mid-day trading on Tuesday. The company traded as low as $0.2805 and last traded at $0.2834. Approximately 1,019,016 shares traded hands during trading, a decline of 88% from the average daily volume of 8,376,955 shares. The stock had previously closed at $0.29.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Weiss Ratings lowered shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Wall Street Zen upgraded shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

aTyr Pharma Trading Down 8.3%

The firm has a 50-day moving average of $0.45 and a 200 day moving average of $0.57. The company has a market cap of $25.04 million, a P/E ratio of -0.41 and a beta of 0.91.

aTyr Pharma (NASDAQ:ATYR) last issued its earnings results on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. On average, equities analysts predict that aTyr Pharma, Inc. will post -0.44 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in aTyr Pharma stock. Bank of America Corp DE boosted its stake in aTyr Pharma, Inc. (NASDAQ:ATYR) by 139.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 303,559 shares of the company’s stock after purchasing an additional 176,859 shares during the quarter. Bank of America Corp DE owned about 0.31% of aTyr Pharma worth $237,000 as of its most recent SEC filing. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc (NASDAQ: ATYR) is a biotechnology company focused on developing medicines that regulate immune responses and treat serious diseases. The company’s research is based on the therapeutic potential of extracellular functions of tRNA synthetases, a group of proteins traditionally known for their role in protein production but increasingly studied for their involvement in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein based on histidyl-tRNA synthetase.